Keytruda or Opdivo Denied by Insurance? How to Appeal

Pembrolizumab (Keytruda) and nivolumab (Opdivo) are the most widely prescribed cancer immunotherapies in the world — with FDA approvals spanning over 30 cancer types combined. Despite their established evidence base, insurance denials for these checkpoint inhibitors are common. Here is how to build an appeal that wins.

Why Insurers Deny Keytruda and Opdivo Claims

Both Keytruda and Opdivo denials follow predictable patterns that can be directly challenged with specific regulatory and clinical arguments:

• "Not medically necessary / indication not met" — The insurer's reviewer disagrees that the drug is appropriate for your specific clinical situation, despite FDA approval and NCCN guidelines
• "Off-label use" — The specific indication used for your cancer type does not have its own separate FDA approval, even when NCCN Compendium supports coverage; under ACA Section 2719A, non-grandfathered plans must cover NCCN-included regimens
• "PDL1 threshold not met" — For certain Keytruda indications (first-line NSCLC monotherapy requires PDL1 ≥50%); if results are near threshold, the specific test used matters
• "Step therapy — try chemotherapy first" — Both Keytruda and Opdivo are FDA-approved as first-line therapy for many indications; requiring prior chemotherapy contradicts FDA approval and NCCN Category 1 evidence
• "Biomarker testing required" — MSI/MMR testing, PDL1 testing, or TMB testing not documented in the PA submission
• "Experimental/investigational" — Not applicable to FDA-approved indications; cite the specific approval date and pivotal trial

Under ACA §2719 and ERISA §1133, you have the right to a written denial explanation, internal appeal, and independent External Independent Review: Complete Guide" class="auto-link">external review.

How to Appeal a Keytruda or Opdivo Denial

Step 1: Verify Biomarker Testing Is Complete and Documented

For Keytruda (pembrolizumab): confirm PDL1 testing with the 22C3 antibody (FDA-approved companion diagnostic for most indications), MSI/MMR testing, and TMB testing as applicable to your cancer type. For Opdivo (nivolumab): PDL1 testing requirements vary by indication and clinical setting; confirm which testing is required for your specific indication. Missing biomarker documentation is frequently the correctable cause of PA denials.

Step 2: Get Your Oncologist to Write a Comprehensive Letter of Medical Necessity

The letter must include your exact cancer type, stage, histology, and complete biomarker profile; the specific NCCN guideline recommendation (Category 1, 2A, or 2B) for your cancer type and treatment setting; the FDA indication and approval date; results of any prior treatments that have failed; and why alternative treatments are not appropriate for your specific case.

Step 3: For Off-Label Denials — Cite NCCN Compendium Coverage Rights

Both CMS and most commercial insurers accept the NCCN Compendium as an authoritative source for off-label oncology coverage. Cite the specific NCCN guideline recommendation level for your indication and state that under your insurer's own oncology drug coverage policy, NCCN-included regimens are covered. For CheckMate and KEYNOTE trial data supporting your specific indication, your oncologist should reference the pivotal trial in the letter of medical necessity.

Step 4: For Step Therapy Denials — Cite First-Line Approval and Survival Outcomes

For first-line NSCLC with Keytruda (PDL1 ≥50%): KEYNOTE-024 demonstrated 80.2% vs. 72.4% OS at 3 years favoring pembrolizumab over platinum chemotherapy (p=0.002). For Opdivo plus Yervoy in first-line RCC: CheckMate 214 demonstrated significantly improved OS in intermediate/poor risk patients. First-line FDA approval status makes step therapy requirements clinically unjustifiable and legally challengeable.

Step 5: Request Expedited Review for Urgent Cancer Treatment

Under ACA §2719, request expedited review with a decision within 72 hours. Have your oncologist provide written certification that treatment delay would jeopardize your health. Cancer treatment delays are precisely the situation Congress intended expedited review to address.

Step 6: Request External Review After Internal Denial

After an internal appeal denial, request independent external review through your state insurance department or DMHC (California). An independent reviewer applying NCCN and FDA standards — rather than the insurer's proprietary criteria — evaluates your case. External reviews overturn 40–60% of insurer denials.

What to Include in Your Appeal

• Insurance denial letter with the specific denial reason and policy provision identified
• Your member ID and claim number
• Complete biomarker testing results with specific antibodies and testing methodology
• Oncologist's letter of medical necessity addressing each denial criterion with specific FDA and NCCN citations
• NCCN Clinical Practice Guidelines in Oncology for your cancer type showing the recommendation category for the specific regimen
• Relevant pivotal trial citations (KEYNOTE series for Keytruda; CheckMate series for Opdivo)
• FDA drug label showing the specific approved indication

Fight Back With ClaimBack

Keytruda and Opdivo denials are serious — and they are among the most successfully overturned when specific FDA approvals and NCCN Category 1 evidence are clearly cited. A well-constructed oncology appeal citing your clinical situation alongside regulatory standards makes it very difficult for an insurer to sustain a denial. ClaimBack generates a professional appeal letter in 3 minutes. Start your free claim analysis → Free analysis · No credit card required · Takes 3 minutes

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs External Insurance Appeal